Jared Freml, PharmD
Pharmacists looking to cut the cost of cancer therapy often focus on quick therapy starts to achieve the fastest response. But a new study suggests that savings—and safety—also can be bolstered by stopping treatments when they no longer are effective or pose an undue risk for adverse reactions.
Patients receiving tyrosine kinase inhibitors (TKIs), for example, who maintain a deep molecular response for at least two years should be considered for